Therapeutic Strategies to Augment Muscle Rehabilitation

该项目的长期目标是开发新的治疗策略，改善肌肉萎缩， 加速脊髓损伤等病理条件下的肌肉康复。本申请是 符合克里斯托弗和达纳里夫瘫痪法案（CDRPA）的愿景，该法案促进了 开展类似工作的科学家之间的互动，以进一步增进了解， 为数百万患有瘫痪的美国人提供有效的治疗干预措施。“CDRPA鼓励 协调研究，以防止冗余，并希望加快发现更好的治疗方法， 治疗，同样重要的是，改善瘫痪患者今天的日常生活”。拟议 应用程序呈现了一组富有成效的科学家之间的独特合作， 互补的专业知识和对肌肉和运动功能恢复的共同兴趣。这队 国家专家探索了一个新的研究领域，重点是利用 调节肌肉生长的药理学/分子疗法与新兴康复结合 干预措施。 这项为期2年的申请的具体目标是：1）确定新的药理学策略， 改善废用/去负荷引起的肌肉萎缩，促进肌肉恢复; 2）验证一种新的 脊髓不完全损伤动物模型的康复策略的评估。该项目将 在快速药理学开发领域提供重要的临床前数据，并将为 更临床相关的脊髓损伤模型。靶向药物要么被批准用于人类， 使用或它们在临床开发中，并将允许快速转化为动物模型。该提案规定， 一些独特的机会，并提出了一个重要的一步，在翻译向人体试验。的 个别研究的结果也将为肌肉的科学基础做出重要的新贡献。 康复和脊髓损伤。

The long-range of this project is to develop novel therapeutic strategies that ameliorate muscle atrophy and accelerate muscle rehabilitation following pathological conditions such as spinal cord injury. This application is consistent with the vision of the Christopher and Dana Reeve Paralysis Act (CDRPA) which promotes the interaction of scientists conducting similar work to further enhance understanding and expedite the search for effective treatment interventions for millions of Americans living with paralysis. "The CDRPA encourages coordination of research to prevent redundancies and hopefully hasten discovery of better treatments and cures and, as importantly, to improve the daily lives today for those living with paralysis". The proposed application presents a unique collaboration between a group of productive scientists with diverse, yet complimentary expertise and a common interest in the recovery of muscle and motor function. This team of national experts explores a new area of research focusing on complimentary treatment strategies utilizing pharmacological/molecular therapies modulating muscle growth in conjunction with emerging rehabilitation interventions. The specific objectives of this 2 year application are: 1) To identify novel pharmacological strategies to ameliorate muscle atrophy induced by disuse/unloading and promote muscle recovery; 2) To validate a new animal model of incomplete spinal cord injury for the assessment of rehabilitation strategies. This Project will provide important preclinical data in an area of rapid pharmacological development and will set the stage for a more clinical relevant model of spinal cord injury. The drugs that are targeted are either approved for human use or they are in clinical development and will allow rapid translation to animal models. This proposal provides some unique opportunities and presents an important step forward in the translation towards human trials. The results of the individual studies will also make important new contributions to the science base of muscle rehabilitation and spinal cord injury.